Bayer opens in Mozambique

Bayer commits further to growth and expansion strategy in the Southern Africa region

Maputo, 02 November 2017 - Global healthcare and crop science innovation company, Bayer, is cementing its presence in Africa following its formal announcement of the opening of a new local office in Maputo, Mozambique. The move demonstrates the company’s commitment to its growing business interests in Africa. While Bayer will initially have a large focus on the local agricultural sector through its Crop Science Division, it is already present in the country through the distribution of some of its pharmaceuticals, animal health products and anti-malaria programmes.


Mozambique’s Honourable José Condugua Pacheco, Minister of Agriculture and Food Security welcomed Bayer’s investment into the country at a formal opening ceremony in Mozambique’s capital of Maputo today. Minister Pachecho has previously gone on record indicating that his biggest expectation is to attract more investment into the country[1]. Bayer intends on engaging with the Minister as the company’s presence is cemented in Mozambique.


“We believe that we have synergies with the aspirations of the Mozambican government.  This is especially true of our Crop Science Division that is introducing solutions that meets the unique requirements of the region, which is endowed with a range of climatic, soil and water conditions opportune for a diverse range of agricultural production. Bayer has a lot to offer Mozambique with our strong focus on initiatives that can help shape the future of the local agricultural sector that can enable a sustainable, nutritious food supply, says Dr Klaus Eckstein, Bayer’s CEO and Head of Crop Science in Southern Africa.  


In addition, Bayer has already committed to Mozambique through its partnership with Goodbye Malaria and has been on the frontline of the fight against malaria for some years. Malaria remains the most common cause of death in Mozambique.


Current reports indicate that the Mozambican economy is showing signs of recovery after a difficult 2016 with the first quarter GDP growth in 2017 more than double the growth rate of the preceding quarter[2]. In addition, the output of the agricultural sector in Mozambique is expected to register growth of 6.5 percent this year[3].


“With the promising economic trends pointing upwards, we believe that we are coming into Mozambique at the right time to make our contribution in the region, drawing from over 100 years of experience of operating of in the African continent.” concludes Eckstein.


The new Bayer regional office will be based in the capital city, Maputo, and will include sales support from our Crop Science Division, and has an operational team on the ground in differents parts of the country.


1 http://www.worldbank.org/en/country/mozambique/overview   

2 https://macauhub.com.mo/2016/01/12/mozambique-expects-growth-in-agricultural-production-in-201617/

3 https://www.thebusinessyear.com/mozambique-2016/down-on-the-farm/interview


Bayer: Science For A Better Life

Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Its products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen. In fiscal 2016, the Group employed around 115,200 people and had sales of EUR 46.8 billion. Capital expenditures amounted to EUR 2.6 billion, R&D expenses to EUR 4.7 billion. These figures include those for the high-tech polymers business, which was floated on the stock market as an independent company named Covestro on October 6, 2015. For more information, go to www.bayer.co.za



Tasniem Patel,

Mobile +27 82 8732423

Head of Communications for Southern Africa

Email: tasniem.patel@bayer.com


Forward-Looking Statements

This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.